Download PDF
Planta Med 2018; 84(05): 320-328
DOI: 10.1055/s-0043-119886
Pharmacokinetic Investigations
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Comparison of In Vitro Hepatic Scoparone 7-O-Demethylation between Humans and Experimental Animals

Anam Fayyaz
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
,
Seddy Makwinja
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
,
Seppo Auriola
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
,
Hannu Raunio
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
,
Risto O. Juvonen
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
› Author Affiliations
Further Information

Publication History

received 11 April 2017
revised 25 August 2017

accepted 11 September 2017

Publication Date:
26 September 2017 (online)

    Permissions and Reprints

Abstract

Scoparone is a natural bioactive compound in Chinese herbal medicines. It has numerous pharmacological actions, including liver protective, hypolipidemic, antitumor, and anti-inflammatory effects. The primary metabolism route of scoparone is O-demethylation to scopoletin or isoscopoletin catalyzed by CYP enzymes. The aims of our study were to identify the human CYP enzymes catalyzing scoparone 7-O-demethylation to scopoletin and to compare this oxidation reaction in liver microsomes among different species. A high throughput fluorescent-based assay method was developed to determine the scoparone 7-O-demethylation to scopoletin rate. The rate was 100 – 400 nmol/(min×g protein) in mouse and rabbit liver microsomes, 10 – 20 nmol/(min×g protein) in pig microsomes, 1 – 3 nmol/(min×g protein) in human and less than 1 nmol/(min×g protein) in rat liver microsomes. Human CYP1A1 (Km 13 µM and Vmax 0.8 min−1), CYP1A2 (Km 48 µM and Vmax 0.3 min−1), and CYP2A13 (Km 10 µM and Vmax 22 min−1) were the most efficient catalysts of the reaction. The CYP2A6 selective inhibitor pilocarpine and an antibody against mouse CYP2A5 inhibited scoparone 7-O-demethylation to scopoletin in rabbit, mouse, and pig liver microsomes, indicating involvement of CYP2A enzymes in the reaction. Hepatic scoparone 7-O-demethylation to scopoletin differed between species both with respect to the rate of reaction and catalyzing enzymes. These species differences need to be taken into account when testing scoparone pharmacokinetics in animals and humans.

Key words

coumarins - in vitro methods - pharmacokinetics - cytochrome P450 - scoparone - TCM
 

  • References

  • 1 Baxter H, Harborne JB, Moss GP. eds. Phytochemical Dictionary, a Handbook of bioactive Compounds from Plants. 2nd edition. Wallington: CRC Press; 1998: 1515
    Google Scholar
  • 2 Zhang A, Sun H, Wu G, Sun W, Yuan Y, Wang X. Proteomics analysis of hepatoprotective effects for scoparone using MALDI-TOF/TOF mass spectrometry with bioinformatics. OMICS 2013; 17: 224-229
    CrossrefPubMedGoogle Scholar
  • 3 Jang E, Kim BJ, Lee KT, Inn KS, Lee JH. A survey of therapeutic effects of Artemisia capillaris in liver diseases. Evid Based Complement Alternat Med 2015; 2015: 728137
    PubMedGoogle Scholar
  • 4 Fang H, Zhang A, Yu J, Wang L, Liu C, Zhou X, Sun H, Song Q, Wang X. Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome. Sci Rep 2016; 6: 37519
    CrossrefPubMedGoogle Scholar
  • 5 Hung HY, Kuo SC. Recent studies and progression of Yin Chen Hao (Yīn Chén Hāo), a long-term used traditional Chinese medicine. J Tradit Complement Med 2013; 3: 2-6
    CrossrefPubMedGoogle Scholar
  • 6 Huang HC, Weng YI, Lee CR, Jan TR, Chen YL, Lee YT. Protection by scoparone against the alterations of plasma lipoproteins, vascular morphology and vascular reactivity in hyperlipidaemic diabetic rabbit. Br J Pharmacol 1993; 110: 1508-1514
    CrossrefPubMedGoogle Scholar
  • 7 Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004; 113: 137-143
    CrossrefPubMedGoogle Scholar
  • 8 Zhang A, Qiu S, Sun H, Zhang T, Guan Y, Han Y, Yan G, Wang X. Scoparone affects lipid metabolism in primary hepatocytes using lipidomics. Sci Rep 2016; 6: 28031
    CrossrefPubMedGoogle Scholar
  • 9 Park S, Kim JK, Oh CJ, Choi SH, Jeon JH, Lee IK. Scoparone interferes with STAT3-induced proliferation of vascular smooth muscle cells. Exp Mol Med 2015; 47: e145
    CrossrefPubMedGoogle Scholar
  • 10 Cho DY, Ko HM, Kim J, Kim BW, Yun YS, Park JI, Ganesan P, Lee JT, Choi DK. Scoparone inhibits LPS-simulated inflammatory response by suppressing IRF3 and ERK in BV-2 microglial cells. Molecules 2016; 21: E1718
    CrossrefPubMedGoogle Scholar
  • 11 Masuyama H, Mitsui T, Maki J, Tani K, Nakamura K, Hiramatsu Y. Dimethylesculetin ameliorates maternal glucose intolerance and fetal overgrowth in high-fat diet-fed pregnant mice via constitutive androstane receptor. Mol Cell Biochem 2016; 419: 185-192
    CrossrefPubMedGoogle Scholar
  • 12 Gonzalez FJ, Coughtrie M, Tukey RH. Drug Metabolism. In: Knollman B, Chabner B, Brunton L. eds. Goodman & Gilmanʼs the pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2011: 123-143
    Google Scholar
  • 13 Mehta P, Shah R, Lohidasan S, Mahadik KR. Pharmacokinetic profile of phytoconstituent (s) isolated from medicinal plants – A comprehensive review. J Tradit Complement Med 2015; 5: 207-227
    CrossrefPubMedGoogle Scholar
  • 14 Burkina V, Rasmussen MK, Pilipenko N, Zamaratskaia G. Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharmacol Toxicol Methods 2015; 74: 80-92
    CrossrefPubMedGoogle Scholar
  • 15 Yin Q, Sun H, Zhang A, Wang X. Pharmacokinetics and tissue distribution study of scoparone in rats by ultraperformance liquid-chromatography with tandem high-definition mass spectrometry. Fitoterapia 2012; 83: 795-800
    CrossrefPubMedGoogle Scholar
  • 16 Yang D, Yang J, Shi D, Deng R, Yan B. Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor. Br J Pharmacol 2011; 164: 1547-1557
    CrossrefPubMedGoogle Scholar
  • 17 Mennes WC, Van Holsteijn CW, Timmerman A, Noordhoek J, Blaauboer BJ. Biotransformation of scoparone used to monitor changes in cytochrome P450 activities in primary hepatocyte cultures derived from rats, hamsters and monkeys. Biochem Pharmacol 1991; 41: 1203-1208
    CrossrefPubMedGoogle Scholar
  • 18 Horsmans Y, Desager JP, Harvengt C. Scoparone O-demethylase assay is not useful to differentiate the effects of model inducers of cytochrome P-450 in rabbit and guinea pig liver. Life Sci 1993; 53: PL421-PL426
    PubMedGoogle Scholar
  • 19 Witkamp RF, Nijmeijer SM, Mennes WC, Rozema AW, Noordhoek J, Van Miert AS. Regioselective O-demethylation of scoparone (6,7-dimethoxycoumarin) to assess cytochrome P450 activities in vitro in rat. Effects of gonadal steroids and the involvement of constitutive P450 enzymes. Xenobiotica 1993; 23: 401-410
    CrossrefPubMedGoogle Scholar
  • 20 Wang X, Lv H, Sun H, Liu L, Sun W, Cao H. Development of a rapid and validated method for investigating the metabolism of scoparone in rat using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 3883-3890
    CrossrefPubMedGoogle Scholar
  • 21 Nahata A, Dixit VK. Spectrofluorimetric estimation of scopoletin in Evolvulus alsinoides Linn. and Convulvulus pluricaulis Choisy. Indian J Pharm Sci 2008; 70: 834-837
    CrossrefPubMedGoogle Scholar
  • 22 Crespi CL, Miller VP, Stresser DM. Design and application of fluorometric assays for human cytochrome P450 inhibition. Methods Enzymol 2002; 357: 276-284
    PubMedGoogle Scholar
  • 23 Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715
    CrossrefPubMedGoogle Scholar
  • 24 Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72
    CrossrefPubMedGoogle Scholar
  • 25 Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144: 139-147
    CrossrefPubMedGoogle Scholar
  • 26 Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012; 27: 73-88
    PubMedGoogle Scholar
  • 27 Juvonen RO, Kuusisto M, Fohrgrup C, Pitkänen MH, Nevalainen TJ, Auriola S, Raunio H, Pasanen M, Pentikäinen OT. Inhibitory effects and oxidation of 6-methylcoumarin, 7-methylcoumarin and 7-formylcoumarin via human CYP2A6 and its mouse and pig orthologous enzymes. Xenobiotica 2016; 46: 14-24
    CrossrefPubMedGoogle Scholar
  • 28 DeVore NM, Meneely KM, Bart AG, Stephens ES, Battaile KP, Scott EE. Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J 2012; 279: 1621-1631
    CrossrefPubMedGoogle Scholar
  • 29 Raunio H, Juvonen R, Pasanen M, Pelkonen O, Pääkkö P, Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998; 27: 427-432
    CrossrefPubMedGoogle Scholar
  • 30 Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E, Juvonen RO. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP2A6. Br J Pharmacol 1995; 116: 2625-2630
    CrossrefPubMedGoogle Scholar
  • 31 Honkakoski P, Negishi M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Rev 1997; 29: 977-996
    CrossrefPubMedGoogle Scholar
  • 32 Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43: 149-173
    CrossrefPubMedGoogle Scholar
  • 33 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141
    CrossrefPubMedGoogle Scholar
  • 34 Cohen AJ. Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Cosmet Toxicol 1979; 17: 277-289
    CrossrefPubMedGoogle Scholar
  • 35 Anzenbacher P, Soucek P, Anzenbacherová E, Gut I, Hruby K, Svoboda Z, Kvetina J. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Drug Metab Dispos 1998; 26: 56-59
    PubMedGoogle Scholar
  • 36 Lang MA, Gielen JE, Nebert DW. Genetic evidence for many unique liver microsomal P-450-mediated monooxygenase activities in heterogeneic stock mice. J Biol Chem 1981; 256: 12068-12075
    PubMedGoogle Scholar
  • 37 Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Mäenpää J, Edwards RJ, Boobis AR, Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996; 51: 403-411
    CrossrefPubMedGoogle Scholar